Pfizer, Moderna, and AstraZeneca have been running “dress rehearsals” by adapting their current formulations of Covid-19 vaccines to match present known SARS-CoV-2 variants.
If you are not happy with the results below please do another search
50 search results for:
Nearly four months after Intellia Therapeutics – along with partner Regeneron Pharmaceuticals – reinvigorated the CRISPR space with the first-ever clinical evidence that CRISPR gene editing inside the body can be safe and effective, the asset in question was granted Orphan Drug Designation by the U.S. Food and Drug Administration.
Med Ad News spoke with Jon Koch, the new CEO of Fishawack Health. Koch discussed his background, why he joined Fishawack Health, and what differentiates the company from others in the healthcare communications space.
A trial assessing an experimental AstraZeneca cancer drug was placed on clinical hold due to safety concerns. The trial pause comes two years after Amgen was also forced to pause a study of a drug within the same class.
F-star Therapeutics announced a new partnership with Janssen Biotech on Oct. 20, only one month after presenting an optimistic trial-in-progress update to the public on the clinical-stage biopharma company’s tetravalent dual T-cell agonist FS120 at the European Society for Medical Oncology 2021 Conference.
British health authorities, as well as global experts, are closely watching a subtype of the Delta variant that appears to be rising in the UK.
A booster dose of the Covid-19 vaccine developed by Pfizer Inc. and German partner BioNTech SE restored efficacy to 95.6 percent against the virus, including the Delta variant, data released by the companies from a large study showed on Oct. 21.
Japan’s Shionogi & Co. Ltd. said on Oct. 20 the company started a Phase II/III clinical trial for the drugmaker’s Covid-19 vaccine candidate.
Novartis agreed to expand the company’s fill-and-finish support for the Pfizer/BioNTech Covid-19 vaccine by using manufacturing facilities in Ljubljana, Slovenia, to fill at least 24 million doses in 2022, the Swiss drugmaker said on Oct. 21.
The U.S. Food and Drug Administration on Oct. 20 authorized booster doses of the Covid-19 vaccines from Moderna Inc. and Johnson & Johnson, and the regulatory agency said Americans can choose a different shot from their original inoculation as a booster.